- Home
- BKKT vs IMAB Comparison
BKKT vs IMAB Comparison
Compare BKKT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKKT
- IMAB
- Stock Information
- Founded
- BKKT 2018
- IMAB 2014
- Country
- BKKT United States
- IMAB United States
- Employees
- BKKT N/A
- IMAB N/A
- Industry
- BKKT Computer Software: Prepackaged Software
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BKKT Technology
- IMAB Health Care
- Exchange
- BKKT Nasdaq
- IMAB Nasdaq
- Market Cap
- BKKT 63.5M
- IMAB 73.9M
- IPO Year
- BKKT N/A
- IMAB 2020
- Fundamental
- Price
- BKKT $13.39
- IMAB $2.29
- Analyst Decision
- BKKT
- IMAB Strong Buy
- Analyst Count
- BKKT 0
- IMAB 2
- Target Price
- BKKT N/A
- IMAB $5.50
- AVG Volume (30 Days)
- BKKT 553.7K
- IMAB 635.7K
- Earning Date
- BKKT 05-12-2025
- IMAB 05-15-2025
- Dividend Yield
- BKKT N/A
- IMAB N/A
- EPS Growth
- BKKT N/A
- IMAB N/A
- EPS
- BKKT N/A
- IMAB N/A
- Revenue
- BKKT $3,710,548,000.00
- IMAB N/A
- Revenue This Year
- BKKT N/A
- IMAB N/A
- Revenue Next Year
- BKKT N/A
- IMAB N/A
- P/E Ratio
- BKKT N/A
- IMAB N/A
- Revenue Growth
- BKKT 128.83
- IMAB N/A
- 52 Week Low
- BKKT $6.81
- IMAB $0.60
- 52 Week High
- BKKT $37.21
- IMAB $2.68
- Technical
- Relative Strength Index (RSI)
- BKKT 60.80
- IMAB 86.59
- Support Level
- BKKT $10.79
- IMAB $1.20
- Resistance Level
- BKKT $13.50
- IMAB $1.47
- Average True Range (ATR)
- BKKT 1.23
- IMAB 0.22
- MACD
- BKKT 0.11
- IMAB 0.12
- Stochastic Oscillator
- BKKT 57.00
- IMAB 78.59
About BKKT Bakkt Holdings Inc.
Bakkt Holdings Inc operates technology that connects the digital economy by offering a platform for crypto and redeeming loyalty points. Its institutional-grade technology platform provides a custody solution that caters to more experienced market participants to store crypto and provides consumers, businesses, and institutions with the ability to buy, sell, and store crypto in a simple, intuitive digital experience accessed via application programming interfaces (APIs) or embedded web experience and Loyalty offers a full spectrum of content that clients can make available to its customers when redeeming loyalty currencies. It generates revenue in the form of Subscription and service and Transaction revenue.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).